{"name":"RenovoRx","slug":"renovorx","ticker":"RNXT","exchange":"NASDAQ","domain":"renovorx.com","description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.","hq":"Los Altos, CA","founded":0,"employees":"","ceo":"Shaun Bagai","sector":"Biotech / Oncology / Drug Delivery","stockPrice":0.94,"stockChange":0.04,"stockChangePercent":4.44,"marketCap":"$44M","metrics":{"revenue":1123000,"revenueGrowth":453.5,"grossMargin":70.9,"rdSpend":6025000,"netIncome":-8814000,"cash":7024000,"dividendYield":0,"peRatio":-23.4,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"RenovoRx Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"RenovoRx reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million and $53.2 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"trial","headline":"RenovoRx Announces Completion of Patient Enrollment in Phase 1 Clinical Trial of Gemcitabine Local Delivery System","summary":"RenovoRx announced the completion of patient enrollment in its phase 1 clinical trial of the gemcitabine local delivery system.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQTk1BamhaVHZWR0trTTVvZHhLbVNhRkF2NG1mZWFRV2R4T1dzQlh4YmxpcUdhMjZfWVQtNzB4LWtrckJJalI2dk5zLW9WbEFDNGtiVnlWYWFGTmZ6V3JueTY2R2tzOXotOWtzNGNpSnhQWFdGVEdjQ3ZwQ0JPU09HWTUxWGVwTlliSnIxdUU4aWc2d0NBZlFiQno5LWxRLUJJamlLQXFLOFZYMEU?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"RenovoRx (RNXT) CFO granted 12,380 RSUs, now reports 134,580 shares - Stock Titan","headline":"RenovoRx (RNXT) CFO granted 12,380 RSUs, now reports 134,580 shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQcWU2SjFEN1VoMkw5S3E4enJxd29Ba2NPOWlvSmI4emFaUFBhbloxQ3k5U1VYNGwxcjREaTBCQmpoUmNjSTJ0SW9LWS1EOTdhel9xbHd2M0VUaTBCSmxiZS1uQXNsbWFqR3lDSWdmNEY2TU5qbk44SmVkeWRrdFZPN2U2WHFXdG5wLVQtbDY1czB5UDBqZE96Tm1uUkVxeDJ4LXMyVmstaXl1WFM3aFl6UEc2QWh3Wmx3a2RDWlF2SHlkcm5ac1I4QkxxMA?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"RenovoRx (RNXT) CFO discloses 25,000 shares bought pre-role - Stock Titan","headline":"RenovoRx (RNXT) CFO discloses 25,000 shares bought pre-role","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-28","type":"pipeline","source":"simplywall.st","summary":"RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future - simplywall.st","headline":"RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQRnptU2hfMXJCUUVPeHVuS3cyV0lGcF96OXdHOWwzdFJPLVVaejRZa2o0eUFMc1NQSUJEUVM5aDFYUTM4WmdyZ3V3LVJwTUh5WWVqQTJNNldSc0hIMDdpYy0wMnNKU3F1cEs1VWF4MUV0TmJ6VEJJR2lOZkE0T24xRGM3NGlBaEdqMHM3N1h5TVE3UUd5bllXWFRkSGh1UzBCMDRGMFdVdTFIWUU2QmZfeVMteTBGSHVrZERTd2NCNnJrcHpkbEdidjl1YUVaWEpTQUNkQzRHMnRLZ9IB3wFBVV95cUxPR2tPQ3Z1SjVpbkEtVy1BQThYZUtlQ2Q3bE44RGJvbzNEN3pnNjFtVXM4ckdkZV9YTy02bEVNYW1aLWswSVphU3BRTENLMGEzUkhvelppVWUwNmJYeU4tWlI0Z1Q3eFhrUDB1d2hNcHdkODlOcXQ1SmxKMGFFbGs1eVJ3VmFUNy1PeXVZQUxDODJBSjB5dU1UeEZsNDdHdTR1ZDAxOHkzay01b0hsQUJIXzNoVFpqcjg2akF6ZGMtMWljV1ExWVBoMHEwaVVROGRtMlJ2VjdpYU1LLWdqTEtZ?oc=5","date":"2025-08-16","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5EUEtQV0NRTVdpbGNYSm5LM0lvejR6UmF1aGUxVjVUMHNpYmNFQ3JLbmZTS3NDb1pQVWpucGhUMnZfVTRScTUzWWN2bXZYVXN5cXdCZXNiZ1E4NzFldGdPREFGdEZRQTJ2?oc=5","date":"2025-07-10","type":"regulatory","source":"MarketBeat","summary":"RenovoRx (RNXT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"RenovoRx (RNXT) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQakx1Mm9LeGh4WEZrT0xFMEpJYzdwLXNKN1RadXJZVzVCR2MzMG1KQ2FCRloxZ2ZJeFpNZU9CNmt1eXJMQTdyNmJfM2xUdmVPUk5TeW9TSHBhQmUzZmtmYVZjUUF2MklwWXFudHJ2elFyUGtMODh0aGljSnBZbkxObTRodHNBaXJfOHZaZ3VLVFZ2NVVEVlMxczBGTXN2c3FvYXZhdDNQWjdGWi1VY1FXR2pRMWZvZ3d2clNkRllObVVMUlZ1SjVZVU54V3l2ZndIU184ZlpB0gHbAUFVX3lxTE9zX0dUMVZnNGJJQlFKR1FxamxVS25wc3lBQzQ3RlZHdERQcGgzNU5WMHFlaHRJZzdwT3djZng3X0tPbEstMWJqbzhveS1QU0gxSUJDWXJPY3FJb0JqNUFqbExSeklCMXhVVVd0VXpXbnFoNjhRR1RMX216R203WGtWOThNWFJJUHcyWnNLbmN5RndKQnBRdDNMd3hERFpmYzBIb29FSktZVnpjLXhWNkJLczlDMVctNGNCYnBBOUM5TkJORTlRNmRYa0lYYXNXWk1hV3BsVjF0amJaaw?oc=5","date":"2025-05-26","type":"pipeline","source":"simplywall.st","summary":"RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment - simplywall.st","headline":"RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxObzF3ODhldERaeDkzLTFMdHViM0FWTV9Gb2dIQUNVSV8yajFvSVZhQzA5dFQtbUlpRTAxTUIyLVRsTG5IRmYtYm0wRmpYS1VjeHJQbTBSNU9DUHNwQjI3NVpuWGR2QURMQmduVng1Q2dOYk5VUFFVeW5mbGtnSE4yLTVzamM3YjNwTVZEMWNwZHNLR1lGdHRpX1BaalEzLXA5NEpkVTY5OEJUMnExMjVsdVBhcGF4RWdEOUVmQVlWSWVWUktGM21J?oc=5","date":"2024-12-12","type":"pipeline","source":"BioPharma APAC","summary":"RenovoRx and Imugene Join Forces for Oncolytic Virus Therapy Using TAMP Platform - BioPharma APAC","headline":"RenovoRx and Imugene Join Forces for Oncolytic Virus Therapy Using TAMP Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE14WHpVYkhGWko5QnJEajZhLWc0VHBBbG5nRTl2bjRIelViVWFkZHdEVUhMY0lLM0pRbm1YMk5fcWZ1YVVjUkRNbnJ2cE9YVmdET2c?oc=5","date":"2023-04-24","type":"pipeline","source":"Yahoo! Finance Canada","summary":"RenovoRx, Inc. (RNXT) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"RenovoRx, Inc. (RNXT) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE90T08xZDFZWUlKcGlwdUZJbko4NERVdTd1TFdHS2RmcXd6RGlhR25HNDFTMld6TmhGejVFajZLWFJmVGNzbzl6bHVjRlR3eW5SR1hGRWYtZnJwdw?oc=5","date":"2021-08-30","type":"pipeline","source":"MarketBeat","summary":"RenovoRx (RNXT) Stock Price, News & Analysis - MarketBeat","headline":"RenovoRx (RNXT) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5iM1ZhRHhjdjYybHpMTktxYVkxdlJkZnJPdkllbW9KazZGalFCZ0ZsUzJ6Yk5WaENKLW9TdFFNVG5TZmkxaUxjQXlKeEhqUDEtTUJJMmxjMVdqeWZW?oc=5","date":"2021-08-11","type":"pipeline","source":"TradingView","summary":"RNXT Stock Price and Chart — NASDAQ:RNXT - TradingView","headline":"RNXT Stock Price and Chart — NASDAQ:RNXT","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Pfizer","Merck"],"therapeuticFocus":["Oncology","Drug Delivery"],"financials":{"source":"sec_edgar","revenue":43000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":43000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":6025000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-8814000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":8118000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.94,"previousClose":0.9,"fiftyTwoWeekHigh":1.45,"fiftyTwoWeekLow":0.7,"fiftyTwoWeekRange":"0.701 - 1.45","fiftyDayAverage":0.95,"twoHundredDayAverage":1.07,"beta":1.22,"enterpriseValue":33735436,"forwardPE":-23.4,"priceToBook":6.33,"priceToSales":39.42,"enterpriseToRevenue":30.04,"enterpriseToEbitda":-2.81,"pegRatio":0,"ebitda":-12008000,"ebitdaMargin":0,"freeCashflow":-6420250,"operatingCashflow":-10973000,"totalDebt":212000,"debtToEquity":3.9,"currentRatio":4.02,"returnOnAssets":-92.6,"returnOnEquity":-225.6,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":6.69,"targetHighPrice":13,"targetLowPrice":2.75,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.8,"institutionHeldPercent":14.6,"sharesOutstanding":45052706,"floatShares":40895242,"sharesShort":617404,"shortRatio":2.62,"shortPercentOfFloat":1.7,"epsTrailing":-0.32,"epsForward":-0.04,"revenuePerShare":0.03,"bookValue":0.15,"officers":[{"age":59,"name":"Dr. Ramtin  Agah M.D.","title":"Founder, Chairman of Board & Chief Medical Officer"},{"age":48,"name":"Mr. Shaun R. Bagai","title":"CEO, Secretary & Director"},{"age":55,"name":"Ms. Leesa  Gentry","title":"Chief Clinical Officer"},{"age":70,"name":"Mr. Mark  Voll","title":"CFO & Principal Accounting Officer"},{"age":null,"name":"Mr. Robert  Strasser","title":"Vice President of Operations and R&D"},{"age":null,"name":"Mr. Ryan  Witt","title":"Senior VP and Head of Corporate Strategy & Partnerships"},{"age":67,"name":"Mr. Ronald B. Kocak CPA, CGMA","title":"VP of Finance & Controller"}],"industry":"Biotechnology","irWebsite":"","website":"https://renovorx.com","phone":"650 284 4433"}}